晚期前列腺癌治疗4周时早期前列腺特异性抗原与阿比特龙和恩扎卢胺治疗:一项国际合作分析
这项回顾性多中心分析纳入1358例接受一线下一代激素治疗(NGHT)的转移性去势抵抗性前列腺癌(mCRPC)患者,评估治疗4周时PSA下降≥30%(PSA4w30)与总生存(OS)的关系。583例(52%)达到PSA4w30,其OS长于无变化和进展者;PSA4w30与12周PSA下降≥30%强相关,作者认为4周PSA变化有助于指导早期治疗转换决策。
要点
- 1358例mCRPC患者中583例(52%)在NGHT治疗4周时PSA下降≥30%。
- PSA4w30者中位OS为23个月,优于无变化者17个月和进展者13个月。
- 4周PSA变化与12周PSA变化强相关(ρ=0.91)。
核心结论
- NGHT治疗最初4周的PSA变化与mCRPC临床结局强相关,可帮助指导早期治疗转换决策。
- 阿比特龙/恩扎卢胺治疗后4周的PSA变化对判断患者结局重要,临床实践应考虑。
研究设计与样本
- 回顾性多中心分析,纳入2006年1月6日至2017年12月31日在全球13个癌症中心接受一线NGHT的mCRPC患者。
- 共1358例,其中1133例有4周PSA,948例同时有4周和12周PSA。
- PSA反应定义为较基线下降≥30%,进展定义为较基线升高≥25%。
- 采用landmark多变量Cox回归分析OS,校正既往化疗,并将癌症中心作为共享 frailty 项。
主要发现
- 583例(52%)达到PSA4w30;中位OS为23个月(95%CI 21-25),无变化者中位OS为17个月(95%CI 15-18),进展者中位OS为13个月(95%CI 10-15)。
- PSA12w30与较低死亡率相关:中位OS 22个月 vs 14个月;HR=0.57(95%CI 0.48-0.67;p<0.001)。
- PSA4w30与PSA12w30强相关(ρ=0.91;95%CI 0.90-0.92;p<0.001)。
- 达到PSA4w30的患者中432/494(87%)随后达到PSA12w30。
- 4周时进展的152例患者中11例(7%)后续达到PSA12w30,占总体人群的1%。
临床怎么用
- 作者认为,NGHT治疗最初4周的PSA变化与mCRPC临床结局强相关,可帮助指导早期治疗转换决策。
- 作者指出,阿比特龙/恩扎卢胺治疗后4周的PSA变化对判断患者结局重要,临床实践应考虑。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study. OBJECTIVE: To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed at baseline and at 4 and/or 12wk after treatment. PSA response was defined as a ≥30% decline (progression as a ≥25% increase) from baseline. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Association with overall survival (OS) was analysed using landmark multivariable Cox regression adjusting for previous chemotherapy, including cancer centre as a shared frailty term. RESULTS AND LIMITATIONS: We identified 1358 mCRPC patients treated with first-line NGHT (1133 had PSA available at 4wk, and 948 at both 4 and 12wk). Overall, 583 (52%) had a PSA4w30; it was associated with longer OS (median: 23; 95% confidence interval [CI]: 21-25) compared with no change (median: 17; 95% CI: 15-18) and progression (median: 13; 95% CI: 10-15). A PSA12w30 was associated with lower mortality (median OS 22 vs 14; hazard ratio=0.57; 95% CI=0.48-0.67; p<0.001). PSA4w30 strongly correlated with PSA12w30 (ρ=0.91; 95% CI=0.90-0.92; p<0.001). In total, 432/494 (87%) with a PSA4w30 achieved a PSA12w30. Overall, 11/152 (7%) patients progressing at 4wk had a PSA12w30 (1% of the overall population). CONCLUSIONS: PSA changes in the first 4wk of NGHT therapies are strongly associated with clinical outcome from mCRPC and can help guide early treatment switch decisions. PATIENT SUMMARY: Prostate-specific antigen changes at 4wk after abiraterone/enzalutamide treatment are important to determine patients' outcome and should be taken into consideration in clinical practice.
引用
- Rescigno P, Dolling D, Conteduca V, et al. Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. Eur Urol Oncol. 2019. PMID: 31307958. doi:10.1016/j.euo.2019.06.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。